Searchable abstracts of presentations at key conferences on calcified tissues
Previous issue | Volume 5 | ECTS2016 | Next issue

43rd Annual European Calcified Tissue Society Congress

Rome, Italy
14 May 2016 - 17 May 2016

Card image cap

Oral Communications

Clinical trials, FGF-23 and focal osteoporosis

ba0005oc3.1 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effect of odanacatib on bone density and estimated bone strength in postmenopausal women: a CT-based sub-study of the phase 3 long-term odanacatib fracture trial (LOFT)

Langdahl Bente , De Villiers Tobias , Keaveny Tony M , Engelke Klaus , Genant Harry , Ather Shabana , Giezek Hilde , Lombardi Antonio , Leung Albert , de Papp Anne

Odanacatib (ODN), a selective oral inhibitor of cathepsin K, is in development for the treatment of osteoporosis. In the Phase 3, Long-Term ODN Fracture Trial (LOFT; NCT00529373), ODN significantly reduced fracture risk. This imaging sub-study primarily investigated the effect of ODN on volumetric BMD (vBMD) of the lumbar spine (LS) and total hip (TH) using quantitative computed tomography (QCT).Women aged ≥65 without baseline radiographic vertebra...

ba0005oc3.2 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Effects of Denosumab (Dmab) on bone matrix mineralization: results from the phase 3 FREEDOM trial

Dempster David W , Brown Jacques P , Yue Susan , Farlay Delphine , Rizzo Sebastien , Song Jenny , Wang Andrea , Wagman Rachel B , Boivin Georges

Low fracture (FX) incidence has been demonstrated in women with postmenopausal osteoporosis (PMO) treated with DMAb for up to 10 years in the FREEDOM extension [Bone ASBMR 2015]. Bone biopsy-based assessment of DMAb’s effects at the tissue level has demonstrated a low remodelling rate consistent with DMAb’s mechanism of action (Reid JBMR 2010; Brown JBMR 2014). From FREEDOM, we report the effects of DMAb on bone matrix mineralization in women who un...

ba0005oc3.3 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Vitamin D supplementation reduces pregnancy chances: a randomized, placebo-controlled trial

Rasmussen Gitte Bloch , Mosekilde Leif , Vestergaard Peter , Heickendorff Lene , Ulbjerg Niels , Langdahl Bente , Rejnmark Lars

Introduction: Low 25-hydroxyvitamin D (25OHD) levels are frequently found in fertile women and associated with low birth weight, reduced fertility and adverse pregnancy outcomes.Objective: We investigated the effects of vitamin D supplementation on birth weight, fertility, and delivery complications in women planning pregnancy with low 25OHD levels.Methods: This was an investigator-initiated double-blind, randomized, placebo-contro...

ba0005oc3.4 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis

Gossiel Fatma , McCloskey Eugene , Walsh Jennifer , Naylor Kim , Peel Nicola , Eastell Richard

FGF-23 is a phosphate regulating hormone and its production may be stimulated by circulating levels of 1,25-dihydroxyvitamin D (1,25-(OH)2D). Teriparatide administration increases levels of 1,25-(OH)2D, however it is unclear whether this mediates changes in FGF-23 levels. The aims were i) to determine the effect of teriparatide treatment on circulating levels of FGF-23 and 1,25-(OH)2D and ii) to describe the time course of effect in postmenopau...

ba0005oc3.5 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Low serum iron is associated with high serum FGF23 in elderly men: the Swedish MrOS study

Lewerin Catharina , Ljunggren Osten , Nilsson-Ehle Herman , Karlsson Magnus K , Herlitz Hans , Lorentzon Mattias , Ohlsson Claes , Mellstrom Dan

Introduction: Fibroblast growth factor (FGF23) is a hormone derived from osteoblasts and osteocytes being involved in calcium and phosphate homeostasis, where serum iron (S-Fe) has been suggested as a potential mediator of FGF23 regulation. The aim was to determine whether iron status is a determinant of FGF23 in elderly men.Methods: The MrOS (osteoporotic fractures in men is a population based study of elderly men, in the Gothenburg part, (median age of...

ba0005oc3.6 | Clinical trials, FGF-23 and focal osteoporosis | ECTS2016

Focal osteoporosis associated with hip fracture involves both trabecular and cortical bone; a 3D cortical bone mapping study of cases and controls using clinical CT

Poole Ken , Skingle Linda , Gee Andrew , Turmezei Thomas , Johannesdottir Fjola , Blesic Karen , Rose Collette , Vindlacheruvu Madhavi , Donnell Simon , Vaculik Jan , Dungl Pavel , Horak Martin , Stepan Jan , Reeve Jonathan , Treece Graham

Focal cortical thinning and loss of trabecular structure in the proximal femur is associated with hip fracture. We analysed clinical computed tomography (CT) scans in cases and controls to explore their contributions to hip fracture in women.We used cortical bone mapping (CBM) and statistical parametric mapping (SPM) after combining women with hip fracture from FEMCO and Prague Hip Joint in Trauma studies (n=138, 52 Trochanteric and 86 Femoral N...